NET Cancer Day
November 10 is World NET Awareness Day and we need your help!
Use your social media accounts to help us spread the news about NET Cancers. Using the power of social media we are hoping to highlight key messages on the plight of NET Cancer patients.
• 5-7 out of every 100.000 are diagnosed with #netcancer each year http://incalliance.org
• 50% of #netcancer patients have secondary growths at diagnosis http://incalliance.org
• 60-80% of patients are diagnosed with #NETCANCER at advanced stage showing the need for symptom awarenesshttp://incalliance.org
Veranstaltungen zum NET Cancer Day 2015 des Netzwerk Neuroendokrine Tumoren (NeT) e. V.
For more information: www.netzwerk-net.de
Hotel NH München Neue Messe
Überregionaler Neuroendokriner Tumortag des Netzwerk Neuroendokrine Tumoren (NeT) e. V., mit zahlreiche Vorträgen und Workshops rund um die Neuroendokrinen Neoplasien
Ergebnisse der neuesten Studien zu NET
The Pheochromocytoma and Paraganglioma 2015 International patient Conference.
This patient conference is being held in Syracuse, New Jersey on the 5-7 November (the end of this week) and will be Webcast free of charge, for anyone interested in pheochromocytoma, paraganglioma and MEN.
(Please note that anyone wishing to register during this last week prior to conference should contact Matt Capogreco the organiser directly, on his email email@example.com.
Blog post by Ron Hollander.
The International Neuroendocrine Cancer Alliance (INCA) held its annual Summit and Member meeting in Oxford, England. The assembled representatives from NET groups in 18 nations focused on ways to spread awareness, assist NET groups, and support research for NET patients worldwide.
Blog post by Bill Claxton.
Good news from Vienna, ECC 2015, the European Cancer Congress,
announced by Philippe Ruszniewski, MD, head of gastroenterology and pancreatology at Beaujon Hospital, in Clichy, France.
“Treatment with the novel peptide receptor radionuclide therapy (PRRT) Lutathera significantly increased progression-free survival (PFS) over octreotide LAR (Sandostatin) in patients with advanced midgut neuroendocrine tumors (NETs), according to findings from the phase III NETTER-1 trial presented at the 2015 European Cancer Congress.”
Medical abstract is here (www.europeancancercongress) and a press release is here (www.onclive.com).
NET Cancer patient experience, including diagnosis, disease impact and management, quality of life, and knowledge and awareness levels.
|Patient Perspective||Time to Diagnosis|
“We hope these survey findings help give people with this type of cancer a voice, and educate the public and healthcare professionals about the personal side of this disease.” said Teodora Kolarova, INCA President.
– Medical students are thought to assume that the simplest explanation is usually the best, i.e., it is usually correct to look for common rather than exotic causes for disease. Doctors learn to expect common conditions, hence the phrase
“If you hear hoofbeats, think horses, not zebras.”